ZY
Income statement / Annual
Last year (2021), Zymergen Inc.'s total revenue was $16.74 M,
an increase of 26.04% from the previous year.
In 2021, Zymergen Inc.'s net income was -$361.79 M.
See Zymergen Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$16.74 M |
$13.28 M |
$15.42 M |
| Cost of Revenue |
$69.72 M
|
$84.82 M
|
$102.64 M
|
| Gross Profit |
-$52.98 M
|
-$71.53 M
|
-$87.22 M
|
| Gross Profit Ratio |
-3.16
|
-5.38
|
-5.66
|
| Research and Development Expenses |
$159.12 M
|
$90.85 M
|
$50.72 M
|
| General & Administrative Expenses |
$83.01 M
|
$60.08 M
|
$61.25 M
|
| Selling & Marketing Expenses |
$23.65 M
|
$18.63 M
|
$24.14 M
|
| Selling, General & Administrative Expenses |
$106.66 M
|
$78.70 M
|
$85.39 M
|
| Other Expenses |
$175.51 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$265.78 M
|
$169.56 M
|
$136.10 M
|
| Cost And Expenses |
$335.50 M
|
$254.37 M
|
$238.74 M
|
| Interest Income |
$64,000.00
|
$492,000.00
|
$4.92 M
|
| Interest Expense |
$14.71 M
|
$10.96 M
|
$2.94 M
|
| Depreciation & Amortization |
$20.70 M
|
$18.71 M
|
$15.20 M
|
| EBITDA |
-$326.33 M |
-$232.58 M |
-$218.65 M |
| EBITDA Ratio |
-19.49
|
-17.51
|
-14.18
|
| Operating Income Ratio |
-20.73
|
-18.15
|
-15.38
|
| Total Other Income/Expenses Net |
-$14.71 M
|
-$21.15 M
|
$318,000.00
|
| Income Before Tax |
-$361.73 M
|
-$262.24 M
|
-$236.80 M
|
| Income Before Tax Ratio |
-21.61
|
-19.74
|
-15.36
|
| Income Tax Expense |
$51,000.00
|
-$49,000.00
|
$8,000.00
|
| Net Income |
-$361.79 M
|
-$262.19 M
|
-$236.80 M
|
| Net Income Ratio |
-21.61
|
-19.74
|
-15.36
|
| EPS |
-4.87 |
-2.68 |
-2.42 |
| EPS Diluted |
-4.87 |
-2.68 |
-2.42 |
| Weighted Average Shares Out |
$74.31 M
|
$97.94 M
|
$97.94 M
|
| Weighted Average Shares Out Diluted |
$74.31 M
|
$97.94 M
|
$97.94 M
|
| Link |
|
|
|
